Sweden · Delayed Price · Currency is SEK Orexo AB Earnings Call Transcripts
Fiscal Year 2026
-
Transformation continued with one-time costs and staff reductions, while R&D advanced key AmorphOX-based projects. Financials showed negative cash flow and higher OpEx due to settlements and legal fees, with SEK 233 million cash remaining. DOJ settlement and partnering efforts remain key near-term priorities.
-
Divestment of Zubsolv completed, shifting focus to proprietary pipeline and technology partnerships. Net revenue was SEK 5 million, with significant transition-related payments and ongoing DOJ investigation. Key clinical milestones and partnerships are expected to drive future value.
-
AmorphOX is now the exclusive R&D focus, with late-stage projects OX640 and IZIPRY prioritized for value creation. Key milestones include FDA filings, pivotal trials, and expanding partnerships, supported by a strong financial position post-Zubsolv sale.
Fiscal Year 2025
-
Divestment of Zubsolv U.S. to Dexcel Pharma brought significant cash inflow and a strategic pivot to the AmorphOX platform, with a leaner organization and focus on R&D. Continued operations saw negative EBITDA in Q4, but the company is well-capitalized for at least two years.
-
U.S. rights to Zubsolv were sold to Dexcel Pharma for $91 million plus potential earn-outs, enabling debt redemption and funding for pipeline projects. Organizational changes include U.S. staff transfer and streamlined operations, while the company focuses on advancing its development pipeline and partnering opportunities.
-
Q3 saw strong R&D progress, especially in GLP-1 and OX390, with BARDA funding secured for the latter. Revenue declined year-over-year due to FX and contract impacts, but gross margin improved and 2025 positive EBITDA guidance is reaffirmed.
-
Sales remain strong with positive EBITDA, driven by Zubsolv and a robust U.S. presence. The pipeline features innovative nasal delivery products and the AmorphOX platform, which enables stable, high-bioavailability formulations for both small and large molecules. Partnership discussions and market adaptation are ongoing.
-
Q2 results were impacted by a one-time SEK 9 million rebate and negative FX, but core U.S. business remained stable with improved margins and cost control. Pipeline progress continued for OX124 (IC3) and OX640, and 2025 guidance was reaffirmed.
-
Q1 delivered stable revenues and positive EBITDA, with Zubsolv sales steady despite volume declines from payer policy changes. OX640 attracted strong partner interest after a successful trial, and 2025 guidance was reaffirmed.
Fiscal Year 2024
-
Full-year and Q4 EBITDA turned positive, driven by cost reductions and stable U.S. sales. Litigation resolution and asset restructuring improved strategic flexibility, while digital assets were impaired due to regulatory hurdles. OX124 FDA resubmission faces supplier delays.
-
Q3 saw Zubsolv stabilize in demand and commercial growth, but revenues declined due to public segment and FX. OX124 approval was delayed by FDA data requests, and legal uncertainties persist. 2024 guidance is maintained, with a strategic review underway and positive EBITDA expected.
-
Q2 2024 saw a rebound in Zubsolv sales and positive EBITDA, but OX124 approval was delayed by an FDA CRL requiring more device data. Abstral royalties declined as contracts expired, while European Zubsolv revenues grew. Financial guidance for 2024 is maintained amid ongoing legal and regulatory uncertainties.